AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22935052
Drug: Placebo 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 10 mg orally three times daily for 14 days followed by Domperidone 10 mg orally three times daily for 14 days
Trial: 19834698
Drug: Dopaminergic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopaminergic drugs (e.g., levodopa)
Trial: 19834698
Drug: Nondopaminergic drugs
RxNorm normalized name: MAO B Inhibitors, dopaminergic anti-parkinson drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nondopaminergic drugs (e.g., folic acid, methylphenidate, aplindore, levetiracetam, Neu 120)
Trial: 19834698
Drug: Newly developed
RxNorm normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Newly developed drugs with known mode of action
Trial: 15764958
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of Abacavir (ABC) administered once daily
Trial: 15764958
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of Abacavir (ABC) administered twice daily
Trial: 10641957
Drug: Sustained-release diltiazem
RxNorm normalized name: diltiazem
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sustained-release diltiazem (INTERCEPT trial)
Trial: 26178160
Drug: Melatonin 20
RxNorm normalized name: melatonin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 20 mg orally each night for 1 week
Trial: 20679619
Drug: EOC +
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EOC + P (epirubicin 50 mg/m(2), oxaliplatin 130 mg/m(2), capecitabine 1,000 mg/m(2)/d + P 9 mg/kg every 3 weeks)
Trial: 20679619
Drug: EOC (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EOC (standard dose)
Trial: 18215666
Drug: Primary intraosseous
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary intraosseous injection of 1.4 mL of 2% lidocaine with epinephrine
Trial: 18215666
Drug: Repeated intraosseous
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated intraosseous injection given 30 minutes after the primary injection
Trial: 18215666
Drug: Mock injection
RxNorm normalized name: mockernut extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mock injection at 30 minutes
Trial: 16618470
Drug: Active Physical
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Physical Treatment (APT, n = 52)
Trial: 16618470
Drug: Cognitive-Behavioral Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavioral Treatment (CBT, n = 55)
Trial: 16618470
Drug: Combined Treatment
RxNorm normalized name: POISON IVY/OAK/SUMAC EXTRACTS COMBINED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Treatment (CT, n = 55)
Trial: 14725386
Drug: New toothbrush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New toothbrush plus plaque disclosing tablet (SIGNAL Integral)
Trial: 14725386
Drug: Marketed toothbrush
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Marketed toothbrush (Oral B Cross Action)
Trial: 8219659
Drug: Cilazapril (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril (2.5 mg/day) after placebo treatment
Trial: 3305057
Drug: N-acetylcysteine (NAC),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC), peroral dose 200 mg three times daily
Trial: 29249276
Drug: Adjunctive rifampicin
RxNorm normalized name: rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjunctive rifampicin (600 mg or 900 mg per day for 2 weeks)
Trial: 22820788
Drug: Hydroxychloroquine, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine, 400 mg once daily for 48 weeks
Trial: 18275682
Drug: Supraphysiological doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supraphysiological doses of PYY3-36
Trial: 10529526
Drug: AmF 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AmF 1% F(‐) solution applied twice a year on the enamel surfaces of the first permanent molars for 5 years
Trial: 10529526
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution applied twice a year on the enamel surfaces of the first molars for 5 years
Trial: 10529526
Drug: AmF 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AmF 1% F(‐) solution in low-SMS subjects
Trial: 10529526
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution in low-SMS subjects
Trial: 10529526
Drug: AmF 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AmF 1% F(‐) solution in high-SMS subjects
Trial: 10529526
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution in high-SMS subjects
Trial: 1522289
Drug: 1% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% chlorhexidine gel (daily application for one week)
Trial: 25881564
Drug: Autologous blood
RxNorm normalized name: Banked autologous blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous blood injections (ABIs)
Trial: 19161758
Drug: Levosimendan (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan (12 microg/kg bolus, followed by an infusion of 0.2 microg/kg/min)
Trial: 9474184
Drug: 3-month course
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-month course of 300 mg neoadjuvant cyproterone acetate daily
Trial: 2371437
Drug: Amoxycillin 1
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxycillin 1 g twice daily with probenecid
Trial: 2371437
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose amoxycillin 3 g twice daily
Trial: 782773
Drug: 10 mg/70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/70 kg dextroamphetamine sulfate and 50 mug/kg THC from marihuana cigarette
Trial: 782773
Drug: 10 mg/70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/70 kg dextroamphetamine sulfate and 25 mug/kg THC from marihuana cigarette
Trial: 782773
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of dextroamphetamine and marihuana
Trial: 23216615
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg apixaban, twice daily
Trial: 23216615
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg apixaban, twice daily
Trial: 21216852
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion during normoglycemia
Trial: 14514589
Drug: Inhaled regular
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled regular insulin (80, 160, or 240 units) via Aerodose insulin inhaler
Trial: 14514589
Drug: Subcutaneously injected
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneously injected regular insulin (8, 16, or 24 units)
Trial: 14514589
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of total insulin absorption (insulin AUC) versus total metabolic effect (GIR-AUC)
Trial: 10718776
Drug: Risedronate (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate (30 mg single oral dose)
Trial: 1417176
Drug: Surgery and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery and chemotherapy (n = 77)
Trial: 22199063
Drug: 0.1% tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% tacrolimus ointment, twice daily for 6 months
Trial: 22199063
Drug: 0.05% fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% fluticasone propionate cream, once daily for 6 months
Trial: 21589776
Drug: Massage therapy
RxNorm normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage therapy (head, neck, face, shoulder, hand, leg, and back massage every night for one month)
Trial: 21589776
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no intervention except standard treatment)
Trial: 18416219
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular starch in combination with Ringer Lactate solution (LMSRL)
Trial: 2224167
Drug: First line
RxNorm normalized name: ALCOHOL 0.75 mL in 1 mL TOPICAL CLOTH [First Line Alcohol Wipes]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First line chemotherapy (monthly FEC)
Trial: 487347
Drug: Disulfiram implant
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Disulfiram implant
Trial: 487347
Drug: No-implant control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-implant control
Trial: 26448264
Drug: Perampanel 2,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perampanel 2, 4, 8, or 12 mg
Trial: 27869305
Drug: Perampanel 8
RxNorm normalized name: perampanel 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perampanel 8 mg (PGTCS group)
Trial: 17945070
Drug: Mycobacterium vaccae
RxNorm normalized name: Mycobacterium vaccae
DrugBank: Mycobacterium vaccae (DB18449)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mycobacterium vaccae vaccination as an adjunct to anti-tuberculosis treatment
Trial: 17945070
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (anti-tuberculosis treatment without Mycobacterium vaccae vaccination)
Trial: 16297299
Drug: Polyelectrolyte solution
RxNorm normalized name: SUPER-VIAL HYPERLYTE MULTIELECTROLYTE CONC INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyelectrolyte solution (group PS), 21 infants
Trial: 17698196
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of 1.25 mg of bevacizumab at baseline and 6 weeks (n = 22)
Trial: 17698196
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of 2.5 mg of bevacizumab at baseline and 6 weeks (n = 24)
Trial: 17698196
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of 1.25 mg of bevacizumab at baseline and sham injection at 6 weeks (n = 22)
Trial: 17698196
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of 1.25 mg of bevacizumab at baseline and 6 weeks with photocoagulation at 3 weeks (n = 22)
Trial: 12421428
Drug: 50% insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% insulin lispro and 50% neutral protamine lispro (Mix50)
Trial: 10523401
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg/d, starting at 12 to 16 weeks of gestation, administered at time 1 (on awakening)
Trial: 10523401
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg/d, starting at 12 to 16 weeks of gestation, administered at time 2 (8 hours after awakening)
Trial: 10523401
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg/d, starting at 12 to 16 weeks of gestation, administered at time 3 (before bedtime)
Trial: 10523401
Drug: Aspirin (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (any time) for women with a positive tolerance-hyperbaric test
Trial: 10523401
Drug: Aspirin (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (any time)
Trial: 388762
Drug: Antithymocyte globulin
RxNorm normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithymocyte globulin (ATG) - 14 daily doses in addition to standard immunosuppressive therapy (azathioprine and prednisone)
Trial: 388762
Drug: Antithymocyte globulin
RxNorm normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithymocyte globulin (ATG) - 14 daily doses
Trial: 31172407
Drug: GC+w‐iniparib (iniparib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GC+w‐iniparib (iniparib 11.2 mg/kg on days 1 and 8 with gemcitabine 1000 mg/m2 and carboplatin AUC 2 every 3 weeks)
Trial: 31172407
Drug: GC+tw‐iniparib (iniparib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GC+tw‐iniparib (iniparib 5.6 mg/kg on days 1, 4, 8, and 11 with gemcitabine 1000 mg/m2 and carboplatin AUC 2 every 3 weeks)
Trial: 23938061
Drug: Ropinirole (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropinirole (0.25 to 4 mg)
Trial: 21761740
Drug: Maixuekang capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maixuekang capsule
Trial: 21761740
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular heparin calcium (Subilin)
Trial: 21761740
Drug: Maixuekang capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maixuekang capsule and low molecular heparin calcium (Subilin)
Trial: 16413249
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg omeprazole
Trial: 21565525
Drug: Maternal age,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal age, intimate partner violence, illicit drug and alcohol use during pregnancy, reproductive history
Trial: 19092462
Drug: Topical lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lidocaine 2% jelly
Trial: 16284061
Drug: Mifepristone 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 25 mg given twice on day 1 followed by 4 days of ethinyl estradiol (EE) 20 microg in the morning and placebo at night
Trial: 16284061
Drug: Mifepristone 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 25 mg given twice on day 1 followed by 4 days of twice daily placebo
Trial: 11771434
Drug: Glyco A
RxNorm normalized name: glycolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyco A cream (12% glycolic acid)
Trial: 11771434
Drug: Kefrane cream
RxNorm normalized name: Efrane
DrugBank: Enflurane (DB00228)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Kefrane cream (0.05% retinoic acid)
Trial: 3797105
Drug: Increased plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased plasma L-phenylalanine
Trial: 3797105
Drug: Decreased plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decreased plasma L-phenylalanine
Trial: 26903605
Drug: Intralesional pentamidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional pentamidine (120 μg/mm² lesion area, 3 injections over 5 days)
Trial: 26903605
Drug: Intralesional pentamidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional pentamidine (240 μg/mm², 3 injections)
Trial: 26903605
Drug: Intralesional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional therapy with antimony (3 injections over 5 days)
Trial: 26903605
Drug: Intralesional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional therapy with antimony (5 injections over 11 days)
Trial: 26903605
Drug: Intralesional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional therapy with antimony (5 injections)
Trial: 18287130
Drug: Ciclesonide 320
RxNorm normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciclesonide 320 mcg once daily
Trial: 15200038
Drug: Transdermal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal treatment (n = 52)
Trial: 15200038
Drug: 0.2% glyceryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% glyceryl trinitrate ointment (n = 37)
Trial: 9209220
Drug: Hydrocortisone hemisuccinate
RxNorm normalized name: Hydrocortisone Hemisuccinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone hemisuccinate 50 mg/kg
Trial: 27430394
Drug: Anma therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anma therapy (Japanese massage, AMT), 40-min session per week for 8 weeks
Trial: 27430394
Drug: Anma therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anma therapy (Japanese massage, AMT), single session
Trial: 24633595
Drug: Supervised aerobic
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Supervised aerobic exercise during chemotherapy (n = 78)
Trial: 24633595
Drug: Resistance exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistance exercise during chemotherapy (n = 82)
Trial: 24633595
Drug: Subgroup analysis
RxNorm normalized name: RSV subgroup A stabilized prefusion F protein
DrugBank: Recombinant stabilized RSV A prefusion F antigen (DB18713)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subgroup analysis for estrogen receptor-positive tumors
Trial: 24633595
Drug: Subgroup analysis
RxNorm normalized name: RSV subgroup A stabilized prefusion F protein
DrugBank: Recombinant stabilized RSV A prefusion F antigen (DB18713)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subgroup analysis for patients receiving ≥85% of planned chemotherapy
Trial: 22533660
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment with SBP target <130 mm Hg
Trial: 22533660
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with SBP target <140 mm Hg
Trial: 21109302
Drug: Statin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin treatment (mainly atorvastatin 24 mg per day)
Trial: 21109302
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (no statin treatment)
Trial: 21109302
Drug: Statin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin treatment (mainly atorvastatin)
Trial: 16463007
Drug: Alendronate 5
RxNorm normalized name: ALENDRONATE 5MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate 5 mg daily (men and premenopausal women) / 10 mg daily (postmenopausal women)
Trial: 16463007
Drug: Alendronate 5
RxNorm normalized name: ALENDRONATE 5MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate 5 mg daily / 10 mg daily
Trial: 12651757
Drug: Turbuhaler with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Turbuhaler with terbutaline sulphate (0.5 mg/10 kg, maximum 2.0 mg)
Trial: 12651757
Drug: pMDI connected
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pMDI connected to Nebuhaler spacer with terbutaline sulphate (0.5 mg/10 kg, maximum 2.0 mg)
Trial: 8866702
Drug: GHB, 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHB, 15 mg/kg
Trial: 8866702
Drug: GHB, 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHB, 30 mg/kg
Trial: 1502480
Drug: Cimetidine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (400 mg or 800 mg)
Trial: 20234783
Drug: Valsartan 160
RxNorm normalized name: valsartan 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 160 mg plus amlodipine 5 mg
Trial: 20234783
Drug: Losartan 100
RxNorm normalized name: LOSARTAN 100MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 100 mg plus amlodipine 5 mg
Trial: 25769960
Drug: Tai-chi group-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tai-chi group-based exercise program (60 minutes, twice weekly for 48 weeks)
Trial: 19620850
Drug: Paroxetine 20
RxNorm normalized name: PARoxetine 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine 20 mg once daily at night for 12 weeks
Trial: 16399263
Drug: Related prime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Related prime (e.g. 'piano')
Trial: 10907154
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CG) - dermatological standard treatment
Trial: 9310109
Drug: Eltenac gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltenac gel
Trial: 8376682
Drug: Oral milrinone
RxNorm normalized name: Milrinone
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral milrinone with converting enzyme inhibitors
Trial: 27473306
Drug: High-dose (HD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose (HD) influenza vaccine
Trial: 27473306
Drug: Standard-dose (SD)
RxNorm normalized name: Alphanine SD
DrugBank: Coagulation Factor IX Human (DB13152)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose (SD) influenza vaccine
Trial: 25636721
Drug: Calcium supplement
RxNorm normalized name: Calcium supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplement intake
Trial: 23972968
Drug: Tiotropium 18
RxNorm normalized name: TIOTROPIUM 18MCG CAP,INHL,6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium 18 mcg QD